Molecular imaging and personalized medicine: an uncertain future

Area of Science:

• Biomedical imaging
• Pharmacology
• Personalized medicine

Background:

• Regulatory bodies like the FDA recognize imaging's role in drug approval.
• The pharmaceutical industry uses imaging to improve drug development efficiency and efficacy.
• Molecular imaging offers unique regional insights for targeted therapies, complementing in vitro methods.

Purpose of the Study:

• To demonstrate how molecular imaging can improve the efficiency and efficacy of routine treatments with targeted drugs.
• To highlight the potential of molecular imaging in personalized medicine, particularly in oncology.
• To address the challenges hindering the integration of molecular imaging into routine clinical practice.

Main Methods:

• The study discusses the application of molecular imaging in conjunction with targeted drug therapies.
• It emphasizes the need for early engagement between therapeutic companies and imaging developers.
• Clinical trials are proposed to assess the medical and financial efficacy of imaging-guided treatments.

Main Results:

• Molecular imaging provides crucial regional and functional information for personalized medicine, unattainable by in vitro methods.
• It has the potential to significantly aid in patient selection and early response assessment for high-cost treatments.
• Addressing regulatory, financial, and practical barriers is essential for widespread adoption.

Conclusions:

• Molecular imaging is vital for the future of personalized medicine, offering a powerful tool for targeted drug development and patient management.
• Reducing the cost and time associated with developing imaging agents is a priority.
• Regulatory authorities and therapeutic companies must collaborate to align regulations with the needs of personalized medicine and molecular imaging.